Cargando…

Adoptive immunotherapy for gastric cancer using zoledronate-activated killer cells: A prospective observational study

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Yamaguchi, Yoshiyuki, Katata, Yousuke, Sano, Fuminori, Tanioka, Hiroaki, Okawaki, Makoto, Yamamura, Masahiro, Nagasaka, Takeshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2022
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637851/ https://www.ncbi.nlm.nih.gov/pubmed/34881040 http://dx.doi.org/10.3892/mco.2021.2454

Ejemplares similares

Adoptive immunotherapy for gastric cancer using zoledronate-activated killer cells: A prospective observational study
por: Yamaguchi, Yoshiyuki, et al.
Publicado: (2020)

Neutrophil‑to‑lymphocyte ratio before each chemotherapy line predicts clinical outcomes in patients with unresectable gastric cancer
por: Tanioka, Hiroaki, et al.
Publicado: (2023)

Concordance of acquired mutations between metastatic lesions and liquid biopsy in metastatic colorectal cancer
por: Taniguchi, Fumitaka, et al.
Publicado: (2021)

Allogenic natural killer cell immunotherapy of sizeable ovarian cancer: A case report
por: Xie, Silun, et al.
Publicado: (2017)

The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: a prospective observational multicenter study protocol (IVY)
por: Tanioka, Hiroaki, et al.
Publicado: (2019)

Clinical and epigenetic features of colorectal cancer patients with somatic POLE proofreading mutations
por: Kawai, Takashi, et al.
Publicado: (2021)

The bisphosphonate zoledronic acid impairs membrane localisation and induces cytochrome c release in breast cancer cells
por: Senaratne, S G, et al.
Publicado: (2002)

Long‐term (>5‐year) survivors among unresectable or metastatic cancer patients treated with zoledronate‐activated killer cells: Seven case reports
por: Yamaguchi, Yoshiyuki
Publicado: (2022)

Adoptive Natural Killer Cell Immunotherapy for Canine Osteosarcoma
por: Kisseberth, William C., et al.
Publicado: (2021)

Natural killer cells in antitumour adoptive cell immunotherapy
por: Laskowski, Tamara J., et al.
Publicado: (2022)

Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells
por: Milone, M R, et al.
Publicado: (2014)

Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy
por: Lupo, Kyle B., et al.
Publicado: (2019)

Large-scale expansion of γδ T cells and peptide-specific cytotoxic T cells using zoledronate for adoptive immunotherapy
por: YOSHIKAWA, TOSHIAKI, et al.
Publicado: (2014)

CORRIGENDUM: Commentary on Pharmacometrics for Immunotherapy
por: Garrido, MJ, et al.
Publicado: (2017)

Impact of microRNA-29b on nature killer cell in T-cell acute lymphoblastic leukemia
por: Jin, Fengyan, et al.
Publicado: (2021)

Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation
por: Nada, Mohanad H., et al.
Publicado: (2017)

Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies
por: Matosevic, Sandro
Publicado: (2018)

Augmentation by Tumor Necrosis Factor α of the Systemic Therapeutic Effect of Lymphokine‐activated Killer Cells in Adoptive Immunotherapy of Murine Tumor
por: Kato, Kazunori, et al.
Publicado: (1991)

Corrigendum to “Sarcoma Immunotherapy: Past Approaches and Future Directions”
por: D'Angelo, S. P., et al.
Publicado: (2015)

Corrigendum to “Measuring the poverty reduction effects of adopting agricultural technologies in rural Ethiopia: Findings from an endogenous switching regression approach”
por: BelayZegeye, Mesele, et al.
Publicado: (2023)

Adoptive Immunotherapy Strategies with Cytokine-Induced Killer (CIK) Cells in the Treatment of Hematological Malignancies
por: Schmeel, Frederic Carsten, et al.
Publicado: (2014)

Cytokine-induced killer cells as a feasible adoptive immunotherapy for the treatment of lung cancer
por: Chen, Dan, et al.
Publicado: (2018)

Engineering of chimeric natural killer cell receptors to develop precision adoptive immunotherapies for cancer
por: Obajdin, J., et al.
Publicado: (2020)

Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy
por: GRANZIN, MARKUS, et al.
Publicado: (2015)

Corrigendum to ‘single-cell transcriptomics of blood reveals a natural killer cell subset depletion in tuberculosis’ [EBioMedicine 53 (2020) 102686]
por: Cai, Yi, et al.
Publicado: (2022)

Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer
por: Koizumi, W, et al.
Publicado: (2014)

NHE1 is upregulated in gastric cancer and regulates gastric cancer cell proliferation, migration and invasion
por: Xie, Rui, et al.
Publicado: (2019)

Combined Photodynamic and Photothermal Therapy and Immunotherapy for Cancer Treatment: A Review [Corrigendum]
Publicado: (2023)

Corrigendum: treatments for resectable esophageal cancer: from traditional systemic therapy to immunotherapy
Publicado: (2023)

The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies
por: Dosani, T, et al.
Publicado: (2015)

Biodegradable Materials with Disulfide-Bridged-Framework Confine Photosensitizers for Enhanced Photo-Immunotherapy [Corrigendum]
Publicado: (2022)

Analysis of Gastric Body Microbiota by Pyrosequencing: Possible Role of Bacteria Other Than Helicobacter pylori in the Gastric Carcinogenesis
por: Sohn, Sung-Hwa, et al.
Publicado: (2017)

New product development with the innovative biomolecular sublingual immunotherapy formulations for the management of allergic rhinitis [Corrigendum]
Publicado: (2015)

Corrigendum to “Dissecting the genetic heterogeneity of gastric cancer”
por: Hess, Timo, et al.
Publicado: (2023)

MIIP is Downregulated in Gastric Cancer and Its Forced Expression Inhibits Proliferation and Invasion of Gastric Cancer Cells in vitro and in vivo [Corrigendum]
Publicado: (2021)

Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy
por: Schmitz, M, et al.
Publicado: (2007)

Corrigendum to ‘Medical students and the Informal Radiology Curriculum: Adopting the Emergency Radiology Triage Assistant Program (ER-TAP) amid COVID-19’ [Academic Radiology 30/2 (2023) 381–383]
por: Haver, Hana, et al.
Publicado: (2023)

Corrigendum: Comparisons of Gastric Cancer Treatments: East vs. West
por: Bickenbach, Kai, et al.
Publicado: (2012)

A Hybrid Glioma Tumor Cell Lysate Immunotherapy Vaccine Demonstrates Good Clinical Efficacy in the Rat Model [Corrigendum]
Publicado: (2022)

Corrigendum to “Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma Patients”
por: Qian, Lei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cjf16o2l1pivdmemeerad4sgct